CD36 and pancreatic ductal adenocarcinoma: Interestingly, many patients with pancreatic ductal adenocarcinoma (PDAC) are resistant to gemcitabine; CD36 affects gemcitabine resistance by regulating anti-apoptotic proteins, and high CD36 expression in PDAC is critical for poor prognosis [110].